Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Autor: Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35a6a06435710a766e71312c7d53b84
https://doi.org/10.1200/jco.21.00807